Roadmap to control HBV and HDV epidemics in China

doi:10.1016/j.jtbi.2017.04.007

Title: Roadmap to control HBV and HDV epidemics in China

Full Record
Other Related Research

Abstract

Hepatitis B virus (HBV) is endemic in China. Almost 10% of HBV infected individuals are also infected with hepatitis D virus (HDV) which has a 5–10 times higher mortality rate than HBV mono-infection. The aim of this manuscript is to devise strategies that can not only control HBV infections but also HDV infections in China under the current health care budget in an optimal manner. Furthermore, using a mathematical model, an annual budget of 10 billion dollars was optimally allocated among five interventions namely, testing and HBV adult vaccination, treatment for mono-infected and dually-infected individuals, second line treatment for HBV mono-infections, and awareness programs. As a result, we determine that the optimal strategy is to test and treat both infections as early as possible while applying awareness programs at full intensity. Under this strategy, an additional 19.8 million HBV, 1.9 million HDV infections and 0.25 million lives will be saved over the next 10 years at a cost-savings of 79 billion dollars than performing no intervention. Introduction of second line treatment does not add a significant economic burden yet prevents 1.4 million new HBV infections and 15,000 new HDV infections. In conclusion, test and treatment programs are highly efficient inmore »« less

Authors:

Goyal, Ashish ^[1]; Murray, John M. ^[1]

UNSW Australia, Sydney, NSW (Australia)

Publication Date:: 2017-04-23

Research Org.:: Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

Sponsoring Org.:: National Institutes of Health (NIH); USDOE

OSTI Identifier:: 1358168

Report Number(s):: LA-UR-16-28585
Journal ID: ISSN 0022-5193

Grant/Contract Number:: AC52-06NA25396

Resource Type:: Accepted Manuscript

Journal Name:: Journal of Theoretical Biology

Additional Journal Information:: Journal Volume: 423; Journal Issue: C; Journal ID: ISSN 0022-5193

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Subject:: 60 APPLIED LIFE SCIENCES; biological science; health economics; epidemiology; public policy; sexually transmitted infection

Citation Formats


                    Goyal, Ashish, and Murray, John M. Roadmap to control HBV and HDV epidemics in China.  United States: N. p., 2017. 
        Web.  doi:10.1016/j.jtbi.2017.04.007.

Copy to clipboard


                    Goyal, Ashish, & Murray, John M. Roadmap to control HBV and HDV epidemics in China.  United States.  doi:10.1016/j.jtbi.2017.04.007.

Copy to clipboard


                    Goyal, Ashish, and Murray, John M. Sun .  
        "Roadmap to control HBV and HDV epidemics in China".  United States.  doi:10.1016/j.jtbi.2017.04.007.  https://www.osti.gov/servlets/purl/1358168.

Copy to clipboard


                    
@article{osti_1358168,

  title        = {Roadmap to control HBV and HDV epidemics in China},

  author       = {Goyal, Ashish and Murray, John M.},

  abstractNote = {Hepatitis B virus (HBV) is endemic in China. Almost 10% of HBV infected individuals are also infected with hepatitis D virus (HDV) which has a 5–10 times higher mortality rate than HBV mono-infection. The aim of this manuscript is to devise strategies that can not only control HBV infections but also HDV infections in China under the current health care budget in an optimal manner. Furthermore, using a mathematical model, an annual budget of 10 billion dollars was optimally allocated among five interventions namely, testing and HBV adult vaccination, treatment for mono-infected and dually-infected individuals, second line treatment for HBV mono-infections, and awareness programs. As a result, we determine that the optimal strategy is to test and treat both infections as early as possible while applying awareness programs at full intensity. Under this strategy, an additional 19.8 million HBV, 1.9 million HDV infections and 0.25 million lives will be saved over the next 10 years at a cost-savings of 79 billion dollars than performing no intervention. Introduction of second line treatment does not add a significant economic burden yet prevents 1.4 million new HBV infections and 15,000 new HDV infections. In conclusion, test and treatment programs are highly efficient in reducing HBV and HDV prevalence in the population. Under the current health budget in China, not only test and treat programs but awareness programs and second line treatment can also be implemented that minimizes prevalence and mortality, and maximizes economic benefits.},

  doi          = {10.1016/j.jtbi.2017.04.007},

  journal      = {Journal of Theoretical Biology},

  number       = C,

  volume       = 423,

  place        = {United States},

  year         = {2017},

  month        = {4}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (DOE)

Publisher's Version of Record

DOI: 10.1016/j.jtbi.2017.04.007

Other availability

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil

Journal Article Goyal, Ashish ; Romero-Severson, Ethan Obie - PLoS ONE

Hepatitis D virus (HDV), which requires the presence of hepatitis B virus (HBV), is a deadly yet neglected disease that rapidly leads to liver cancer and disease-induced mortality. This co-dependence creates complex transmission dynamics that make it difficult to predict the efficacy of interventions aimed at HBV and/or HDV control in endemic regions, such as certain municipalities of Brazil, where up to 65% of HBV-infected persons are co-infected. We created a mathematical model that captures the joint transmission dynamics of HBV and HDV, incorporating mother-to-child, sexual and household transmission. With an aim to minimize the number of total infections andmore »« less
DOI: 10.1371/journal.pone.0203831

Full Text Available
Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs

Journal Article Huang, Hai, E-mail: HHai3552@sina.cn - Toxicology and Applied Pharmacology

Background: Although current antiviral treatments (nucleoside analogs, NAs) for chronic hepatitis B virus (HBV) infection are effective in suppressing HBV-DNA replication, their clinical outcomes can be compromised by the increasing drug resistance and the inefficiency in promoting HBsAg/HBeAg seroconversion. Objectives: In this study, we will explore possible effects and mechanism of a natural product baicalin (BA) with the anti-HBV efficacy of entecavir (ETV), a first-line anti-HBV drug, in HBV-DNA, HBsAg/HBeAg seroconversion and drug-resistance. Methods: The co-effects of BA and ETV were conducted in wild-type/NA-resistance mutant HBV cell lines and DHBV-infected duckling models. HBV-DNA/RNAs, HBsAg/HBeAg, host factors (hepatocyte nuclear factors) weremore »« less
DOI: 10.1016/J.TAAP.2017.03.016
Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver

Journal Article Reaiche-Miller, Georget Y. ; Thorpe, Michael ; Low, Huey Chi ; ... - Virology

Nucleos(t)ide analogues that inhibit hepatitis B virus (HBV) DNA replication are typically used as monotherapy for chronically infected patients. Treatment with a nucleos(t)ide analogue eliminates most HBV DNA replication intermediates and produces a gradual decline in levels of covalently closed circular DNA (cccDNA), the template for viral RNA synthesis. It remains uncertain if levels of cccDNA decline primarily through hepatocyte death, or if loss also occurs during hepatocyte mitosis. To determine if cccDNA survives mitosis, growing ducklings infected with duck hepatitis B virus (DHBV) were treated with the nucleoside analogue, Entecavir. Viremia was suppressed at least 10{sup 5}-fold, during amore »« less
DOI: 10.1016/J.VIROL.2013.08.014
Expression of the hepatitis B virus genome in chronic hepatitis B carriers and patients with hepatocellular carcinoma

Journal Article Bowyer, S.M. ; Dusheiko, G.M. ; Schoub, B.D. ; ... - Proc. Natl. Acad. Sci. U.S.A.; (United States)

The authors examined the methylation status of CCGG sites in hepatitis B virus (HBV) DNA to determine whether methylation could be responsible for the selective expression of the HBV surface gene in chronic hepatitis B infection and hepatocellular carcinoma. Infected liver tissue from patients with low levels of viral replication was analyzed for HBV DNA copy number per haploid cell genome. Total cellular DNA, with sufficient HBV DNA, was digested with the restriction endonucleases Msp I and Hpa II, to determine whether the HBV DNA was methylated, or HindIII, to determine whether the HBV DNA was integrated or episomal. Themore »« less
DOI: 10.1073/pnas.84.3.847
Diagnostic and prognostic significance of the IgM antibody to the Hepatitis delta virus

Journal Article Farci, P. ; Gerin, J.L. ; Aragona, M. ; ... - JAMA, J. Am. Med. Assoc.; (United States)

The IgM class antibody to the hepatitis delta virus (HDV) was determined in different clinical categories of hepatitis B surface antigen carriers infected by the HDV (positive in the test for total antibody to HDV). The IgM antibody was found at high titers in each 70 patients with inflammatory liver disease and at a low titer in one six patients with inactive cirrhosis; it was not found in eight carriers with normal liver histology. Testing for Igm antibody to HDV distinguishes hepatitis B surface antigen carriers who have underlying inflammatory HDV liver disease from those with past HDV infection andmore »« less
DOI: 10.1001/jama.1986.03370110065022

Similar Records